<?xml version="1.1" encoding="utf-8"?>
<rdf:RDF xmlns:OMEXlib="http://omex-library.org/"
   xmlns:bqbiol="http://biomodels.net/biology-qualifiers/"
   xmlns:bqmodel="http://biomodels.net/model-qualifiers/"
   xmlns:dc="http://purl.org/dc/terms/"
   xmlns:foaf="http://xmlns.com/foaf/0.1/"
   xmlns:local="http://omex-library.org/NewOmex.omex/NewModel.rdf#"
   xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#">
  <rdf:Description rdf:about="http://omex-library.org/BIOMD0000000234.omex">
    <bqmodel:isDescribedBy rdf:resource="local:00001"/>
    <ns1:keyword xmlns:ns1="http://prismstandard.org/namespaces/basic/2.0/">Biomodels</ns1:keyword>
    <ns2:description xmlns:ns2="http://purl.org/dc/elements/1.1/">&lt;body xmlns="http://www.w3.org/1999/xhtml"&gt;
  &lt;div class="dc:title"&gt;Tham2008 - PDmodel, Tumour shrinkage by gemcitabine and carboplatin &lt;/div&gt;
  &lt;div class="dc:bibliographicCitation"&gt;
    &lt;p&gt;This model is described in the article:&lt;/p&gt;
    &lt;div class="bibo:title"&gt;
      &lt;a href="http://identifiers.org/pubmed/18594002" title="Access to this publication"&gt;A pharmacodynamic model for
    the time course of tumor shrinkage by gemcitabine + carboplatin
    in non-small cell lung cancer patients.&lt;/a&gt;
    &lt;/div&gt;
    &lt;div class="bibo:authorList"&gt;Tham LS, Wang L, Soo RA, Lee SC, Lee
  HS, Yong WP, Goh BC, Holford NH.&lt;/div&gt;
    &lt;div class="bibo:Journal"&gt;Clin. Cancer Res. 2008 Jul; 14(13):
  4213-4218&lt;/div&gt;
    &lt;p&gt;Abstract:&lt;/p&gt;
    &lt;div class="bibo:abstract"&gt;
      &lt;p&gt;PURPOSE: This tumor response pharmacodynamic model aims to
    describe primary lesion shrinkage in non-small cell lung cancer
    over time and determine if concentration-based exposure metrics
    for gemcitabine or that of its metabolites,
    2&amp;apos;,2&amp;apos;-difluorodeoxyuridine or gemcitabine triphosphate, are
    better than gemcitabine dose for prediction of individual
    response. EXPERIMENTAL DESIGN: Gemcitabine was given thrice
    weekly on days 1 and 8 in combination with carboplatin, which
    was given only on day 1 of every cycle. Gemcitabine amount in
    the body and area under the concentration-time curves of plasma
    gemcitabine, 2&amp;apos;,2&amp;apos;-difluorodeoxyuridine, and intracellular
    gemcitabine triphosphate in white cells were compared to
    determine which best describes tumor shrinkage over time. Tumor
    growth kinetics were described using a Gompertz-like model.
    RESULTS: The apparent half-life for the effect of gemcitabine
    was 7.67 weeks. The tumor turnover time constant was 21.8
    week.cm. Baseline tumor size and gemcitabine amount in the body
    to attain 50% of tumor shrinkage were estimated to be 6.66 cm
    and 10,600 mg. There was no evidence of relapse during
    treatment. CONCLUSIONS: Concentration-based exposure metrics
    for gemcitabine and its metabolites were no better than
    gemcitabine amount in predicting tumor shrinkage in primary
    lung cancer lesions. Gemcitabine dose-based models did
    marginally better than treatment-based models that ignored
    doses of drug administered to patients. Modeling tumor
    shrinkage in primary lesions can be used to quantify individual
    sensitivity and response to antitumor effects of anticancer
    drugs.&lt;/p&gt;
    &lt;/div&gt;
  &lt;/div&gt;
  &lt;div class="dc:publisher"&gt;
    &lt;p&gt;This model is hosted on 
  &lt;a href="http://www.ebi.ac.uk/biomodels/"&gt;BioModels Database&lt;/a&gt;
  and identified by: 
  &lt;a href="http://identifiers.org/biomodels.db/BIOMD0000000234"&gt;BIOMD0000000234&lt;/a&gt;.&lt;/p&gt;
    &lt;p&gt;To cite BioModels Database, please use: 
  &lt;a href="http://identifiers.org/pubmed/20587024" title="Latest BioModels Database publication"&gt;BioModels Database:
  An enhanced, curated and annotated resource for published
  quantitative kinetic models&lt;/a&gt;.&lt;/p&gt;
  &lt;/div&gt;
  &lt;div class="dc:license"&gt;
    &lt;p&gt;To the extent possible under law, all copyright and related or
  neighbouring rights to this encoded model have been dedicated to
  the public domain worldwide. Please refer to 
  &lt;a href="http://creativecommons.org/publicdomain/zero/1.0/" title="Access to: CC0 1.0 Universal (CC0 1.0), Public Domain Dedication"&gt;CC0
  Public Domain Dedication&lt;/a&gt; for more information.&lt;/p&gt;
  &lt;/div&gt;
&lt;/body&gt;</ns2:description>
    <ns3:title xmlns:ns3="http://purl.org/dc/elements/1.1/">A pharmacodynamic model for the time course of tumor shrinkage by gemcitabine + carboplatin in non-small cell lung cancer patients</ns3:title>
  </rdf:Description>
  <rdf:Description rdf:about="local:00001">
    <ns4:identifier xmlns:ns4="http://purl.org/dc/elements/1.1/"
       rdf:resource="http://identifiers.org/doi/10.1158/1078-0432.CCR-07-4754"/>
    <ns5:label xmlns:ns5="http://www.w3.org/2000/01/rdf-schema#">Lai-San Tham, Lingzhi Wang, Ross A. Soo, Soo-Chin Lee, How-Sung Lee, Wei-Peng Yong, Boon-Cher Goh &amp; Nicholas H.G. Holford. A pharmacodynamic model for the time course of tumor shrinkage by gemcitabine + carboplatin in non-small cell lung cancer patients. Clinical Cancer Research 14, 13 (2008).</ns5:label>
  </rdf:Description>
</rdf:RDF>

